Status:
ACTIVE_NOT_RECRUITING
BRCA1/2 Flu Vaccine
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Conditions:
BRCA1 Mutation
BRCA2 Mutation
Eligibility:
All Genders
25+ years
Brief Summary
To evaluate immune function in BRCA1/2 mutation carriers without cancer, specifically to determine whether immune function in healthy individuals with germline loss of function BRCA1/2 mutations, impa...
Eligibility Criteria
Inclusion
- Males and females
- Over age 25
- BRCA1 or BRCA2 pathogenic or likely pathogenic mutation
- No personal cancer history apart from non melanoma skin cancer, localized thyroid cancer, in situ cancers of any type
- Participants must sign the informed consent form
Exclusion
- Are allergic to influenza vaccination
- Have received influenza vaccination within the past 6 months
- Require prednisone, methotrexate, or other immunosuppressing medications
- Have HIV infection
- Have a history of solid organ tumor or bone marrow transplant
- Require combination immunotherapy;
- Are on other studies requiring blood draws that might exceed 450 mL total during the period of the influenza vaccine study
Key Trial Info
Start Date :
October 28 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04499534
Start Date
October 28 2019
End Date
June 1 2026
Last Update
October 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104